_ Research & development Research & development Pipeline K-877 Pemafibrate K-321 Ripasudil Two key products undergoing investigation in Europe as part of a global research program are Pemafibrate and Ripasudil: Pemafibrate K-877 FIND OUT MORE Ripasudil K-321 FIND OUT MORE Development Code / Nonproprietary Name Classification Indications Development Phase Pitavastatin HMG-CoA reductase inhibitor Dyslipidemia Pitavastatin/ Ezetimibe HMG-CoA reductase inhibitor/ NPC1L1 inhibitor Dyslipidemia Pemafibrate Selective PPARa modulator Dyslipidemia Non-alcoholic fatty liver Primary biliary cholangitis Pemafibrate/ Tofogliflozin Selective PPARa modulator/ SGLT2 inhibitor – Ripasudil Rho kinase inhibitor Glaucoma and ocular hypertension Fuchs endothelial corneal dystrophy Ripasudil/ Brimonidine Rho kinase inhibitor/Alpha-2 adrenergic receptor agonist Glaucoma and ocular hypertension K-161 – Dry eye Ivermectin – SARS-CoV-2 infections Pipeline Notes Only a product in Clinical Stage is listed. This list does not include all of the products. A product in Clinical Stage is defined as a product for which a regulatory procedure has been made for initiation of a first clinical trial (i.e. Investigational New Drug application in US, Clinical Trial Application in Europe, Clinical Trial Notification in Japan, or a similar process in other regions) and a regulatory procedure for discontinuation of development has not been made or regulatory approval has not been obtained in any regions where approval is anticipated. A product assigned with International Nonproprietary Name (INN) is listed as its nonproprietary name. Otherwise, a development code is used. This list shows the most advanced development phase for a product which is in more than one phase amongst countries and/or regions. In addition, countries and regions where regulatory application for marketing authorization (e.g. New Drug Application in US) has been filed with an approval yet to be granted, are also listed. This list also includes a product in Clinical Stage for new indication(s) even if it has been already approved for different indication(s). For more information on our research and development program visit https://www.kowa.co.jp/eng/business/health/development.html Kowa Pharmaceutical Europe Co. Ltd. 105 Wharfedale Road Winnersh Triangle Wokingham Berkshire, RG41 5RB CONTACT US Our products Livazo Avansee Research & development Pipeline Pemafibrate K-877 Ripasudil K-321 Adverse event reporting Kowa routinely monitors the safety of all its medicines. This includes review of safety data from clinical studies, and collection of reports and cases of adverse events for marketed products. REPORT ADVERSE EVENT Copyrights © 2020 Kowa Pharmaceutical Europe Co. Ltd. All rights reserved. Date of preparation: 11 / 2020 UIN: KPE20 00002 Privacy policy Cookie policy Terms of use